Cas:1190322-01-0 5,7-dibromo-2-chloro-1,3-benzothiazole manufacturer & supplier

Chemical Name:5,7-dibromo-2-chloro-1,3-benzothiazole

CAS.NO:1190322-01-0

Synonyms:5,7-Dibromo-2-chlorobenzo[d]thiazole;2-Chloro-5,7-dibromobenzothiazole

Molecular Formula:C₇H₂Br₂ClNS

Molecular Weight:327.42300

HS Code:2934200090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:41.13000

Exact Mass:324.79600

LogP:4.47470

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5,7-Dibromo-2-chlorobenzo[d]thiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Chloro-5,7-dibromobenzothiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5,7-Dibromo-2-chlorobenzo[d]thiazole Use and application,2-Chloro-5,7-dibromobenzothiazole technical grade,usp/ep/jp grade.

Related News: The agency’s first recommendation was straightforward: “Stop using the Innova SARS-CoV-2 Antigen Rapid Qualitative Test. Destroy the tests by placing them in the trash or return the tests to Innova using the FedEx return label that was included with the recall letter that Innova sent to customers.” 5,7-dibromo-2-chloro-1,3-benzothiazole manufacturer The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 5,7-dibromo-2-chloro-1,3-benzothiazole supplier The New York Times said that the batches being discarded amount to around 60 million doses, citing people familiar with the matter. 5,7-dibromo-2-chloro-1,3-benzothiazole vendor In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase. 5,7-dibromo-2-chloro-1,3-benzothiazole factory A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting.